Encouraging efficacy of a comprehensive therapy consisting of sintilimab, bevacizumab biosimilar IBI305, hypo-fractionated intensity-modulated radiotherapy, and oxaliplatin for a maxillary metastasis from hepatocellular carcinoma: A case report and literature review

Oro-maxillo-facial metastasis from hepatocellular carcinoma (HCC) is very rare, and reports on treating maxillary metastasis from HCC are unavailable. Anti-angiogenesis therapy combined with immunotherapy represented by programmed cell death 1 (PD-1) or its ligand (PD-L1) inhibitor has become the st...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Xuexia, Liu, Qiaodan, Yao, Wei, Zhu, Shuqin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727184/
https://www.ncbi.nlm.nih.gov/pubmed/36505782
http://dx.doi.org/10.3389/fonc.2022.941454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727184/
https://www.ncbi.nlm.nih.gov/pubmed/36505782
http://dx.doi.org/10.3389/fonc.2022.941454

Ejemplares similares